Asset
Zirdafulven
Lantern Pharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05933265 | phase1_2 | active_not_recruiting | 2023-06-09 | 2026-07-28 | Lantern Pharma Inc. | Study of LP-184 in Patients With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.